Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ELCC 2018 | The importance of precision immunotherapy: cost, benefit & toxicity

Giorgio Scagliotti • 11 Apr 2018
ELCC 2018
General

In recent years, there has been a massive increase in the number of different immunotherapeutic agents that can be used in the treatment of cancer. In this interview, Giorgio Scagliotti, MD, PhD, from the University of Turin, Turin, Italy, discusses why it is important that patients are only receiving the most appropriate therapy for their specific form of cancer, in terms of side-effects and the high cost of many of these drugs. This interview was conducted at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.

More from Giorgio Scagliotti

The IASLC: implementing personalized medicine in lung cancer
1:32
The IASLC: implementing personalized medicine in lung cancer
Giorgio Scagliotti • 3 Jul 2019
Predicting response to checkpoint inhibitors and overcoming resistance in lung cancers
1:46
Predicting response to checkpoint inhibitors and overcoming resistance in lung cancers
Giorgio Scagliotti • 3 Jul 2019
Overcoming the challenges of precision medicine in lung cancer
1:53
Overcoming the challenges of precision medicine in lung cancer
Giorgio Scagliotti • 3 Jul 2019
More evidence needed to support checkpoint inhibitor use in late-stage cancer
3:23
More evidence needed to support checkpoint inhibitor use in late-stage cancer
Giorgio Scagliotti • 18 Jan 2019

Related Videos

AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026
How should results from the SABR-5 trial guide future SABR studies?
1:05
How should results from the SABR-5 trial guide future SABR studies?
Robert Olson • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals